Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
Alternative names
allogeneic natural killer cells (2 trials)
autologous mesenchymal stem cells (2 trials)
autologous natural killer cells (1 trial)
aldesleukin (Proleukin) (1 trial)
cd19 car-t cells (1 trial)
conjugate of plasmid dna with linear polyethylenimine 20 kda (pei) (1 trial)
lenalidomide (revlimid) (1 trial)
ss2017 (1 trial)
tocilizumab (actemra) (1 trial)
Acute Disease (Phase 1)
Chronic Periodontitis (Phase 2)
Gingival Recession (Phase 2)
Leukemia (Phase 1)
Leukemia, Myeloid, Acute (Phase 1)
Neuroblastoma (Phase 1)
Periodontitis (Phase 2)
Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 1)
Trials (7 total)
Trial APIs (9 total)